secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2024-07-22T23:59:59+00:00
Accession:  0001493152-24-028595
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma replaces auditor KMJ Corbin with Crowe LLP after KMJ partners join Crowe
--------------------------------------------------------------------------------

- Effective July 17, 2024, Immix dismissed KMJ Corbin & Company LLP and appointed Crowe LLP as its independent registered public accounting firm.
- Change follows the partners and professional staff of KMJ joining Crowe; no disagreements or reportable events in fiscal 2022 or 2023.
- KMJ's audit reports for the two most recent fiscal years were unqualified and contained no adverse or modified opinions.
- KMJ provided a letter agreeing with the dismissal statements, filed as Exhibit 16.1 to this Form 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224028595/0001493152-24-028595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224028595/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer